BICO Group

35.86

SEK

-5.13 %

Less than 1K followers

BICO

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

-5.13%

-10.97%

+16.66%

+11.99%

-10.35%

-15.46%

-80.21%

-61.81%

+163.19%

BICO Group operates in the biotechnology industry and focuses on the development and manufacturing of technologies for cell-based research and medical development. The company's products are aimed at researchers and pharmaceutical companies. The business is global with a main presence in Europe, North America and Asia. BICO Group was founded in 2016 and is headquartered in Gothenburg, Sweden.

Market cap

2.53B SEK

Turnover

7.15M SEK

Revenue

1.95B

EBIT %

-14.85 %

P/E

-

Dividend yield-%

-

Financial calendar

29.4

2025

Interim report Q1'25

8.5

2025

General meeting '25

19.8

2025

Interim report Q2'25

All

Webcasts

Press releases

ShowingAll content types

Press release4/16/2025, 5:00 AM

Invitation to the presentation of BICO’s Interim report Q1 2025

Regulatory press release4/15/2025, 5:00 AM

Correction: Notice to attend Annual General Meeting in BICO Group AB (publ)

Regulatory press release4/7/2025, 5:00 AM

Notice to attend Annual General Meeting in BICO Group AB (publ)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release4/4/2025, 4:00 PM

BICO has entered into an agreement to divest MatTek to Sartorius for USD 80m

BICO, Audiocast with teleconference, Q1'25

Webcast4/29/2025, 8:00 AM

BICO, Audiocast with teleconference, Q1'25

Regulatory press release3/20/2025, 8:00 AM

BICO Publishes Annual and Sustainability Report 2024

BICO, Audiocast with teleconference, Q4'24

Webcast2/19/2025, 9:00 AM

BICO, Audiocast with teleconference, Q4'24

Regulatory press release2/19/2025, 6:00 AM

Publication of BICO Group AB: Year-end report 2024

Regulatory press release2/18/2025, 4:42 PM

BICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 276m

Press release2/5/2025, 6:00 AM

Invitation to the presentation of BICO’s Year-end report 2024

Press release11/28/2024, 10:40 AM

BICO completes the divestment of Nanoscribe

BICO, Audiocast with teleconference, Q3'24

Webcast11/26/2024, 9:00 AM

BICO, Audiocast with teleconference, Q3'24

Regulatory press release11/26/2024, 6:00 AM

Publication of BICO Group Interim Report January-September 2024

Press release11/25/2024, 6:00 PM

CELLINK announces further right-sizing and launches sharpened commercial agenda

Press release11/22/2024, 5:00 PM

BICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 118m

Regulatory press release11/21/2024, 4:50 PM

BICO has entered into an agreement to divest Nanoscribe

Press release11/5/2024, 6:00 AM

Invitation to the presentation of BICO’s interim report Q3, 2024

Regulatory press release10/18/2024, 5:00 AM

BICO’s Calendar for financial reporting: H2 2024 and 2025

Regulatory press release10/9/2024, 5:00 AM

BICO Group AB’s Nomination Committee for the 2025 Annual General Meeting

Press release9/17/2024, 11:00 AM

BICO’ Capital Markets Day 2024: Launch of BICO’s Updated strategy, BICO 2.0

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.